

**IN THE CLAIMS**

Please amend the claims as follows:

1-34. (Canceled)

35. (Previously Presented) 3,11b-*cis*-dihydropyridazinone or a salt thereof.

36. (Previously Presented) A composition consisting of 3,11b-*cis*-dihydropyridazinone, or a salt thereof, in substantially pure form.

37. (Previously Presented) 3,11b-*cis*-dihydropyridazinone or a salt thereof according to claim 35 which is in a (+)-isomeric form.


38. (Previously Presented) A composition comprising 3,11b-*cis*-dihydropyridazinone or a salt thereof, the composition being substantially free of 3,11b-*trans*-dihydropyridazinone.

39. (Previously Presented) A composition comprising 3,11b-*cis*-dihydropyridazinone or a salt thereof with less than 5% of 3,11b-*trans*-dihydropyridazinone.


40. (Previously Presented) The composition according to claim 38 wherein the 3,11b-*cis*-dihydropyridazinone or the salt thereof is a (+)-isomer.

41. (Previously Presented) The composition according to claim 39 wherein the 3,11b-*cis*-dihydropyridazinone or the salt thereof is a (+)-isomer.


42. (Previously Presented) The 3,11b-*cis*-dihydropyridazinone or a salt thereof according to claim 35 in the form of a 2*S*,3*S*,11b*R* isomer having the formula (Ia):



43. (Previously Presented) The 3,11b-*cis*-dihydrotetrabenzazine or a salt thereof according to claim 35 in the form of a 2*R*,3*R*,11b*S* isomer having the formula (Ib):




44. (Previously Presented) The 3,11b-*cis*-dihydrotetrabenazine or a salt thereof according to claim 35 in the form of a 2*R*,3*S*,11*bR* isomer having the formula (Ic):



45. (Previously Presented) The 3,11b-*cis*-dihydrotetrabenazine or a salt thereof according to claim 35 in the form of a 2*S*,3*R*,11*bS* isomer having the formula (Id):


46. (Previously Presented) The 3,11b-*cis*-dihydrotetrabenazine according to claim 35 in the form of a free base.
47. (Previously Presented) The 3,11b-*cis*-dihydrotetrabenazine according to claim 35 in the form of an acid addition salt.
48. (Previously Presented) The acid addition salt of 3,11b-*cis*-dihydrotetrabenazine according to claim 47 wherein the salt is a methane sulphonate salt.
49. (Previously Presented) A pharmaceutical composition comprising 3,11b-*cis*-dihydrotetrabenazine or a salt thereof and a pharmaceutically acceptable carrier.
50. (Previously Presented) The pharmaceutical composition according to claim 49 wherein the 3,11b-*cis*-dihydrotetrabenazine or a salt thereof is a (+)-isomer.
51. (Withdrawn-Previously Presented) A method for the prophylaxis or treatment of a hyperkinetic movement disorder, which method comprises the administration of an effective prophylactic or therapeutic amount of 3,11b-*cis*-dihydrotetrabenazine or a salt thereof.
52. (Withdrawn-Previously Presented) The method according to claim 51 wherein the hyperkinetic movement disorder is selected from Huntington's disease, hemiballismus, senile chorea, tic, tardive dyskinesia and Tourette's syndrome.

53. (Withdrawn-Previously Presented) A process for preparing 3,11b-*cis*-dihydrotetrabenazine, which process comprises the reaction of a compound of formula (II):




with a reagent or reagents suitable for hydrating the 2,3-double bond in the compound of formula (II) and thereafter separating and isolating a desired 3,11b-*cis*-dihydrotetrabenazine isomer form.

54. (Withdrawn-Previously Presented) A process for preparing 3,11b-*cis*-dihydrotetrabenazine, which process comprises subjecting a compound of formula (III):




to conditions for ring-opening the 2,3-epoxide group in the compound of the formula (III), and thereafter separating and isolating a desired 3,11b-*cis*-dihydrotetrabenazine isomer form.

55. (Withdrawn-Previously Presented) A compound of the formula (II):



or a salt thereof.

56. (Withdrawn-Previously Presented) A compound of the formula (III):



or a salt thereof.

57. (Previously Presented) A Mosher's acid ester of 3,11b-*cis*-dihydrotetrabenazine.


58. (Previously Presented) The 3,11b-*cis*-dihydrotetrabenazine or a salt thereof according to claim 35, which consists of greater than 90% 3,11b-*cis*-dihydrotetrabenazine, or a salt thereof.

59. (Previously Presented) A composition comprising 3,11b-*cis*-dihydrotetrabenazine, or a salt thereof, and a pharmaceutically acceptable carrier, wherein the 3,11b-*cis*-dihydrotetrabenazine, or a salt thereof, consists of greater than 90% 3,11b-*cis*-dihydrotetrabenazine, or a salt thereof.


60. (Previously Presented) The composition of claim 59, containing less than 5% of 3,11b-*trans*-dihydrotetrabenazine.

61. (Previously Presented) The composition of claim 59, wherein the 3,11b-*cis*-dihydrotetrabenazine is a (+)-isomer, or a salt thereof.


62. (Previously Presented) The composition of claim 59, wherein in the 3,11b-*cis*-dihydrotetrabenazine is a 2*S*,3*S*,11b*R* isomer having the formula (Ia), or a salt thereof:




63. (Previously Presented) The composition of claim 59, wherein in the 3,11b-*cis*-dihydrotetrabenazine is a 2*R*,3*R*,11b*S* isomer having the formula (Ib), or a salt thereof:



64. (Previously Presented) The composition of claim 59, wherein in the 3,11b-*cis*-dihydrotetrabenazine is a 2*R*,3*S*,11b*R* isomer having the formula (Ic), or a salt thereof:



65. (Previously Presented) The composition of claim 59, wherein in the 3,11b-*cis*-dihydrotetrabenazine is a 2*S*,3*R*,11b*S* isomer having the formula (Id), or a salt thereof:



66. (Previously Presented) The composition of claim 59, wherein in the 3,11b-*cis*-dihydrotetrabenazine is a free base.

67. (Previously Presented) The composition of claim 59, wherein in the 3,11b-*cis*-dihydrotetrabenazine, or a salt thereof is in the form of an acid addition salt.

68. (Previously Presented) The composition of 67, wherein the acid addition salt is a methane sulphonate salt.

69. (New) The composition of claim 49, wherein the 3,11b-*cis*-dihydrotetrabenazine or a salt thereof is present in a therapeutically useful amount.

70. (New) The composition of claim 69, wherein the therapeutically useful amount does not inhibit dopamine transporter (DAT).

71. (New) The composition of claim 69, wherein the therapeutically useful amount is not sedating.